The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment

NCT01796288 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer, Oligometastatic

Interventions

RADIATION: simultaneous radiotherapy
DRUG: Erlotinib

Sponsor

Wu Jieping Medical Foundation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]